01.20.26 -- Deploying A Vendor Life Cycle Oversight Model

Discover how new strategies in CHO cell line development are driving innovation and transforming the future of biologics manufacturing, from enhanced productivity to improved therapeutic quality.

The pharma industry is identifying ways to make processes more sustainable. Learn how nanoparticle engineering technology can both empower sustainability goals and lead to better patient outcomes.

High-volume biologics and home-based care requires specialized expertise. Collaborative partnerships bridge the gap between complex drug-delivery requirements and successful commercial market entry.

Next Generation Manufacturing (NGM) integrates advanced process design, digital innovation, and strategic facility planning to facilitate agile, efficient, and sustainable biopharmaceutical production.

Orphan drug development is a journey marked by challenges at every step. From patient recruitment to aseptic fill finish, overcoming hurdles is critical for bringing life-saving treatments to market.

Leveraging cross-functional coordination between sites, harmonized tech transfers, and synchronized team activities can streamline regulatory submissions and deliver high-quality commercial outcomes.

Accelerating the timeline to tox material can significantly enhance the drug development process, enabling faster IND submissions and providing crucial time savings for toxicology studies.